All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Incyte Corp. could achieve label expansion with the already successful myelofibrosis (MF) drug Jakafi (ruxolitinib) by the end of this year, thanks to a phase III victory in the myeloproliferative neoplasm known as polycythemia vera (PV), which sometimes advances to MF.